Apyx Medical Corporation (NASDAQ: APYX)
FILL OUT THE FORM TO FIND OUT YOUR INVESTOR RIGHTS TO POTENTIAL COMPENSATION »
Hagens Berman Sobol Shapiro LLP alerts investors in Apyx Medical Corporation (NASDAQ: APYX) to the June 17, 2019 Lead Plaintiff deadline in the securities class action pending in the U.S. District Court for the Middle District of Florida.
If you purchased or otherwise acquired securities of APYX between August 1, 2018 and April 1, 2019 and suffered losses you do not need to sign up to be included in the putative class of investors. If you suffered losses in excess of $50,000, you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case. If you wish to serve as a lead plaintiff in this class action contact Hagens Berman Sobol Shapiro LLP. For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing APYX@hbsslaw.com.
According to the complaint, Defendants misled investors during the Class Period by misstating and/or failing to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing did not meet its primary efficacy endpoint; (2) the clinical study did not support the Company’s application for regulatory clearance; and, (3) the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing.
“We’re focused on investors’ losses, certain matters flagged in a recent bearish analyst report, and whether investors may have been misled,” said Hagens Berman partner Reed Kathrein.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.